Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Research

| More

JB Chemicals & Pharmaceuticals - Decent performance in challenging times - ICICI Securities

Posted On: 2020-11-18 01:30:24


JB Chemicals & Pharmaceuticals' (JBCPL) Q2FY21 performance was strong at the operating level, though revenue growth was impacted by deferment of exports sales worth Rs570mn (12.9% of total sales) to Q3FY21. Consolidated revenue declined 2.8% YoY to Rs4.4bn while EBITDA margin improved 280bps YoY to 24.8%. However, adjusted PAT dropped 21.0% to Rs739mn due to low base of tax rate. There has been change in management during Q2FY21 as KKR took over the control by acquiring equity stake from promoters and has appointed Mr Nikhil Chopra as CEO who has been with Cipla for 24 years including 5 years as CEO-India business. We remain positive considering ~45% of total revenues and ~55% of EBITDA contribution is from domestic formulations with strong growth visibility. Reiterate BUY with a revised target price of Rs1,114/share.

- Strong operating performance: India business grew 4.5% YoY driven by chronic portfolio despite acute segment being weak due to lockdown. We believe the growth would improve to double digit in coming quarters as lockdown restrictions have been eased and industry growth has also improved. We expect India revenue to grow at 12.3% CAGR over FY20-FY23E led by continued improvement of MR productivity and the price hike in Metrogyl. Exports revenue dropped 9.4% due to deferment of sales worth Rs570mn. Adjusting for this deferment, growth would have been 14.7%. Gross margin improved 630bps aided by better revenue mix and EBITDA margin was up 280bps despite lower exports revenue.

- Focus on multiple growth levers by new management: As per new management, the company will be leveraging the established strong base and will focus on future value creation through: 1) portfolio ramp-up and build larger brands in India business, 2) Augmenting R&D activities for product filings in regulated and semi-regulated markets, 3) expansion of lozenges business to support CMO business and 4) focus on accelerating growth through business development and strategic partnerships including synergistic acquisitions. We believe successful execution would further accelerate the growth momentum.

- Outlook: We expect 11.3% revenue and 18.0% PAT CAGR over FY20-FY23E led by a healthy 12.3% CAGR in India business and EBITDA margin expansion of 390bps to 25.2. We estimate free cashflow generation of ~Rs9.2bn over the next three years, which can be utilised for shareholder rewards and business expansion.

- Valuations and risks: We raise our FY21E-FY22E EPS by 15-18% primarily on higher margins led by saving in operating expenses. We also raise target P/E(x) to 20x from 16x earlier considering significant improvement in return ratios (RoIC 28.6% by FY23E) and focus of new management on accelerating growth. We maintain BUY rating with a revised target price of Rs1,114/share based on 20xSep'22E EPS (earlier: Rs722/share). Key downside risks: Slowdown in India growth, pricing pressure and currency volatility.

Shares of J.B.CHEMICALS & PHARMACEUTICALS LTD. was last trading in BSE at Rs.955.7 as compared to the previous close of Rs. 968.25. The total number of shares traded during the day was 8811 in over 1454 trades.

The stock hit an intraday high of Rs. 968.25 and intraday low of 950. The net turnover during the day was Rs. 8417201.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

What do brokerages say on Burger King India Limited's IPO?

The Phoenix Mills - Potential fund infusion may usher in growth - ICICI Securities

Godrej Agrovet - Beneficiary of 60% increase in palm oil prices - ICICI Securities

Automobiles (wholesale) - Wholesale dispatches rise amidst modest retail trends - ICICI Securities

Oil & Gas - Sector Update - Dec 2020 - ICICI Direct

Phoenix Mills (Buy): Asset monetisation at favourable terms... - ICICI Direct

Aditya Makharia's views on November Auto Sales Number for November 2020 - HDFC Securities

Burger King India - IPO Review - ICICI Direct

Quant Pick - LIC Housing Finance - ICICI Direct

Tech Mahindra - Analyst Meet Update - ICICI Direct

Gladiator Stocks - Crompton Greaves Consumer Electricals - ICICI Direct

Derivatives Monthly Outlook - Nifty support at 12800 for ongoing momentum...

Quant Pick - Sun Pharmaceuticals - ICICI Direct

Monetary Policy - Expectation from YES Securities

Sector Update on Asset Management Companies - Subdued but improvement expected - HDFC Securities

Pre Monetary Policy View - Dec, 2020 - Lakshmi Iyer, President and CIO (Debt) & Head Products, Kotak Mutual Fund

Maintain REDUCE on Siemens - Smart recovery priced in - HDFC Securities

Banking Sector Credit Trends - Growth continues to moderate - HDFC Securities

Q2 FY21 GDP: Light at the end of the tunnel - YES Securities

Siemens - Q4 FY20 Result Update - YES Securities

Super action in Home Loans - SBIN, ICICIBC, AXSB, HDFC and LICHF gaining share - YES Securities

Polymer price tracker - Dec 1, 2020 - PVC prices continue to tread higher - ICICI Securities

Bajaj Finance - Company Update - Dec 2020 - ICICI Direct

Siemens Ltd - Healthy revival in orders and margins - ICICI Securities

Covid Recovery Pulse - Nov 30, 2020 - Festive positivity continues in auto retails, e-way bill generation improves...

Derivatives Weekly View (November 27): Momentum expected to continue in broader markets with Nifty support at 12800...

Derivatives Strategy - Positional Option - ICICI Direct

Preview on RBI Monetary Policy - December 2020 - Shanti Ekambaram, Group President - Consumer Banking, Kotak Mahindra Bank

10 things you should know about Burger King India Limited

Views of HDFC Securities and Acuité Ratings & Research on Q2FY21 GDP Numbers

Rollover Report for November 2020 - December 2020: Angel Broking

Initiating Coverage on Godrej Properties - The housing factory - HDFC Securities

Burger King IPO - Angel Broking

Rollover Analysis - Record foreign inflows pushes Nifty to 13k - YES Securities

Ceramic tiles industry - Market share gains sustain for top branded players - ICICI Securities

Gas sector - CGD: Competition to hit margins, volumes and lead to derating - ICICI Securities

Cement - Prices resilient in Q3; consensus upgrades to continue - ICICI Securities

Specialty chemicals - Price trend in Sep-20 - ICICI Securities

Timken India - Q2FY21 Company Update - ICICI Direct

Upgrade in target price of IDFC First Bank - Angel Broking

Laurus Labs stake acquisition in Richore Lifesciences - Angel Broking

Shares of Lakshmi Vilas Bank (LVB) suspended from trading - Angel Broking

Initiating Coverage on Sundram Fasteners - Fastening growth - HDFC Securities

Astral Poly Technik - Scalability to further improve with storage tanks foray - ICICI Securities

Vardhman Special Steel - Q2FY21 Company Update - ICICI Direct

Initiating Coverage - Advanced Enzyme Technologies - ICICI Direct

L&T - Secures Large Contract - Nov 25, 2020 - Angel Broking

Alembic Pharmaceuticals - Tentative Approval for JV - Angel Broking

Drug launch by Lupin - Tacrolimus Capsules - Angel Broking

Gujarat Gas - Nov 25, 2020 - Angel Broking



Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019